Expert Review of Vaccines最新文献_第2页

Modeling the potential public health and economic impact of different COVID-19 vaccination strategies with an adapted vaccine in the Kingdom of Saudi Arabia. 利用沙特阿拉伯王国的适应疫苗对不同COVID-19疫苗接种策略的潜在公共卫生和经济影响进行建模。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-17 DOI: 10.1080/14760584.2024.2438757

Nadine Al Akoury, Julia Spinardi, Hammam Haridy, Mostafa Moussa, Mohammed Attia Elshabrawi, Carlos Fernando Mendoza, Jingyan Yang, Josie Dodd, Moe H Kyaw, Benjamin Yarnoff

{"title":"Modeling the potential public health and economic impact of different COVID-19 vaccination strategies with an adapted vaccine in the Kingdom of Saudi Arabia.","authors":"Nadine Al Akoury, Julia Spinardi, Hammam Haridy, Mostafa Moussa, Mohammed Attia Elshabrawi, Carlos Fernando Mendoza, Jingyan Yang, Josie Dodd, Moe H Kyaw, Benjamin Yarnoff","doi":"10.1080/14760584.2024.2438757","DOIUrl":"10.1080/14760584.2024.2438757","url":null,"abstract":"Background: The dynamic evolution of the virus causing COVID-19 necessitates the development of adapted vaccines to protect against emerging variants.Research design and methods: A combined Markov-decision tree model estimated the outcomes of alternative vaccination strategies. The Saudi Arabian population was stratified into standard-risk and high-risk subpopulations, defined as either the population comprising individuals aged ≥ 65 years and individuals with at least one comorbidity. The model estimated the health and economic outcomes of vaccination based on age-specific inputs taken from published sources and national surveillance data.Results: The vaccination strategy targeting the elderly and high-risk subpopulation (was estimated to prevent 156,694 cases 12,800 hospitalizations, and 2,919 deaths and result in cost savings of SAR 1,239 million in direct costs and SAR 4,145 million in indirect costs. These gains increased with the vaccination strategies additionally targeting other subpopulations. Compared to the base case (aged ≥65 and those at high-risk), expanding vaccination coverage to 75% of the standard-risk population prevented more cases (323%), hospitalizations (154%), and deaths (60%) and increased the direct (232%) and indirect (270%) cost savings.Conclusions: The adoption of broad vaccination strategies using a vaccine adapted to the dominant variant in circulation would yield substantial benefits in Saudi Arabia.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"27-36"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunogenicity and safety of a live attenuated varicella vaccine in healthy subjects aged between 13 to 55 years: a double-blind, randomized, active-controlled phase III clinical trial in China.

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-02-07 DOI: 10.1080/14760584.2025.2457463

Yang Zhang, Shiyuan Wang, Guifan Li, Jinhui Shi, Xianyun Chang, Hao Zhang, Fengcai Zhu, Jingxin Li, Hongxing Pan, Jinfang Sun

{"title":"Immunogenicity and safety of a live attenuated varicella vaccine in healthy subjects aged between 13 to 55 years: a double-blind, randomized, active-controlled phase III clinical trial in China.","authors":"Yang Zhang, Shiyuan Wang, Guifan Li, Jinhui Shi, Xianyun Chang, Hao Zhang, Fengcai Zhu, Jingxin Li, Hongxing Pan, Jinfang Sun","doi":"10.1080/14760584.2025.2457463","DOIUrl":"10.1080/14760584.2025.2457463","url":null,"abstract":"Background: Adolescents and adults who contract chickenpox are at a higher risk of severe complications. Vaccination with the varicella vaccine (VarV) effectively prevents chickenpox.Research design and methods: In this phase III, single-center, randomized, double-blind, active-controlled trial, 1,200 healthy participants were randomly assigned in a 1:1 ratio to receive two doses of either the test vaccine or the active control vaccine. Varicella-zoster virus (VZV) antibody was detected before vaccination and 42 days after the two doses of vaccination.Results: The lower limits of the 95% CI for the differences in seroconversion rates and geometric mean titer (GMT) ratios between the two groups were greater than their respective pre-set non-inferiority margins. The overall incidence of Adverse events (AEs) and adverse reactions (ARs) in the test group was significantly lower than those in the control group. Additionally, the incidence rates of swelling and fatigue were lower in the test group compared to the control group after vaccination.Conclusions: The test freeze-dried live attenuated VarV demonstrated good immunogenicity and higher safety compared to the active control vaccine in healthy participants aged 13-55 years.Clinical trials registration: www.clinicaltrials.gov identifier: NCT06592456.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"157-164"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strengths and limitations of non-survey-based data sources for assessing adult vaccination coverage in the United States.

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-03-27 DOI: 10.1080/14760584.2025.2483719

Matthew F Daley, Kamonthip J Homdayjanakul, Laura P Hurley, Peng-Jun Lu, Yuping Tsai, Carla L Black, Suchita Patel, James A Singleton, Lori A Crane

{"title":"Strengths and limitations of non-survey-based data sources for assessing adult vaccination coverage in the United States.","authors":"Matthew F Daley, Kamonthip J Homdayjanakul, Laura P Hurley, Peng-Jun Lu, Yuping Tsai, Carla L Black, Suchita Patel, James A Singleton, Lori A Crane","doi":"10.1080/14760584.2025.2483719","DOIUrl":"10.1080/14760584.2025.2483719","url":null,"abstract":"Introduction: Non-survey-based data sources (e.g. electronic health records, administrative claims) have been used to estimate vaccination coverage among US adults. However, these data sources were not collected for research or surveillance purposes and may have substantial limitations. The objectives of this narrative review were to: 1) identify published studies that used non-survey-based data sources to estimate adult vaccination coverage for one or more routinely recommended vaccines; and 2) summarize the strengths and limitations of these data sources for coverage assessments.Areas covered: Thirty-four publications derived from 9 data sources were reviewed: 16 publications were in a general population (i.e. defined by age), 12 were among pregnant women, and 6 were among individuals with chronic health conditions. While several data sources used continuous health insurance enrollment to define the study population, doing so limited generalizability to stably insured populations. Methods for obtaining race and ethnicity data were complex and potentially subject to bias. None of the reviewed studies presented any formal assessment of vaccine data validity.Expert opinion: While multiple non-survey-based data sources have been used to assess adult vaccination coverage in the United States, important limitations exist, including related to generalizability, data validity, and risk of bias.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"230-241"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143700038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in adolescent and adult vaccination in pharmacy and medical settings in the United States, 2018-2024: a database study. 2018-2024 年美国药房和医疗机构中青少年和成人疫苗接种趋势：一项数据库研究。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-22 DOI: 10.1080/14760584.2024.2441255

Yi Zheng, Dong Wang, Ya-Ting Chen, Kunal Saxena, Goran Bencina, Amanda L Eiden

{"title":"Trends in adolescent and adult vaccination in pharmacy and medical settings in the United States, 2018-2024: a database study.","authors":"Yi Zheng, Dong Wang, Ya-Ting Chen, Kunal Saxena, Goran Bencina, Amanda L Eiden","doi":"10.1080/14760584.2024.2441255","DOIUrl":"10.1080/14760584.2024.2441255","url":null,"abstract":"Background: Pharmacies can increase access to vaccines. This study aimed to describe trends in the proportion of adolescent and adult vaccinations administered in pharmacies in the United States from 2018 to 2024.Research design and methods: This was a retrospective cross-sectional analysis of medical and pharmacy claims from commercial health insurance enrollees. We recorded vaccinations received by enrollees ≥9 years of age from 2018 to 2023 (routine vaccines) or 2024 (seasonal vaccines). We calculated the annual proportion of vaccinations occurring in pharmacies and the accumulated percent change in vaccination rate during each year from 2020 onward compared to 2018-2019.Results: The proportion of routine vaccinations occurring in pharmacies was higher among adults than among adolescents. For most routine vaccines, this proportion increased during the study period. The lowest proportion was observed for adolescent human papillomavirus vaccination in 2018 (0.2%), and the highest for herpes zoster vaccination among adults ≥65 years of age in 2023 (88.6%). For all age groups, pharmacy-based vaccination was more common for seasonal influenza and SARS-CoV-2 vaccines than for all routine vaccines except herpes zoster.Conclusions: Pharmacy-based vaccination is increasingly common in the United States, particularly among adults and for seasonal vaccines, and can help increase the overall level of vaccine uptake.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"53-66"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of non-pharmacological interventions on nasopharyngeal Staphylococcus aureus, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae carriage and the change of pneumococcal vaccination in healthy children under 5 years old in Beijing, China.

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-03-13 DOI: 10.1080/14760584.2025.2476521

Qianqian Du, Zhaoqiu Liu, Wei Shi, Xijie Liu, Qinghong Meng, Dongyi Zheng, Kaihu Yao

{"title":"The impact of non-pharmacological interventions on nasopharyngeal Staphylococcus aureus, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae carriage and the change of pneumococcal vaccination in healthy children under 5 years old in Beijing, China.","authors":"Qianqian Du, Zhaoqiu Liu, Wei Shi, Xijie Liu, Qinghong Meng, Dongyi Zheng, Kaihu Yao","doi":"10.1080/14760584.2025.2476521","DOIUrl":"10.1080/14760584.2025.2476521","url":null,"abstract":"Background: We analyzed the impact of non-pharmacological interventions (NPIs) and PCV13 inoculation on nasopharyngeal (NP) carriage of Staphylococcus aureus (Sa), Streptococcus pneumoniae (Sp), Moraxella catarrhalis (Mc), and Haemophilus influenzae (Hi) in healthy children under 5-years-old in Beijing, China.Research design and methods: NP swabs were taken from healthy children seeking routine well-child care at the pediatric preventive health clinic. NP swabs were frozen in Tryptic Soy Broth (TSB) medium and stored at -80°C, and bacterial was detected by culture.Results: From December 2019 to November 2021, 1939 children were enrolled, among whom 278 (14.3%) were found to carry Sa isolates, 115 (5.9%) Sp, 39 (2.0%) Mc, and 6 (0.3%) Hi. The carriage of Sa was highest in infants under 6 months, negatively correlated with Sp and Mc. The Sa carriage rate in infants below 6 months of age rose from 26.7% in pre-NPIs to 32.7% in post-NPIs early. The 13-valent pneumococcal conjugate vaccine (PCV13) uptake rose from 42.3% in December 2019 to 62.3% by October 2021.Conclusions: The broad application of NPIs caused a decline in Sp and Mc carriage among children under 5-years-old, accompanied by an elevation in the Sa carriage rate among infants.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"206-211"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Economic evaluation of childhood pneumococcal conjugate vaccination programs in Qinghai and Hainan provinces, China. 中国青海省和海南省儿童肺炎球菌结合疫苗接种计划的经济评价。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-24 DOI: 10.1080/14760584.2024.2443223

Haonan Zhang, Chaofan Wang, Haijun Zhang, Brian Wahl, Maria Deloria Knoll, Xiaozhen Lai, Hai Fang

{"title":"Economic evaluation of childhood pneumococcal conjugate vaccination programs in Qinghai and Hainan provinces, China.","authors":"Haonan Zhang, Chaofan Wang, Haijun Zhang, Brian Wahl, Maria Deloria Knoll, Xiaozhen Lai, Hai Fang","doi":"10.1080/14760584.2024.2443223","DOIUrl":"10.1080/14760584.2024.2443223","url":null,"abstract":"Background: The burden of pneumococcal disease varies regionally in China, disproportionately affecting children in many provinces such as Qinghai and Hainan. Nevertheless, the absence of a pneumococcal conjugate vaccine (PCV) in the National Immunization Program (NIP) or local programs presents limited coverage. This study evaluated the health and economic impact of including PCV in immunization programs in Qinghai and Hainan.Research design and methods: A decision tree Markov model was constructed to simulate health outcomes and lifetime costs among children under different 13-valent PCV (PCV13) vaccination strategies compared to current practices, from societal and healthcare perspectives. Data on epidemiology, vaccine efficacy, cost, and utility were obtained from the literature and open databases. Sensitivity analyses were conducted to explore parameter uncertainty.Results: Including three-dose PCV13 in provincial programs at NIP coverage (98.91%) could avert 7100 episodes and 118 deaths in Qinghai, and 6200 episodes and 66 deaths in Hainan. It was cost-effective at the $68.2/dose in private market and cost-saving at the United Nations Children's Fund (UNICEF) recommended $25/dose for both provinces. Increasing coverage to 50% or 75% was also cost-effective. Sensitivity analyses confirmed the robustness of the results despite parameter uncertainty.Conclusions: Prioritizing PCV13 in immunization programs in Qinghai and Hainan could effectively reduce disease burden, improve population health, and promote health equity.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"67-80"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Application of reverse cumulative distribution curve and scaled logit model in determining optimal immunogenic dose and prediction of protection of EV71 vaccines. 反向累积分布曲线和比例logit模型在EV71疫苗最佳免疫原剂量确定和保护预测中的应用。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-18 DOI: 10.1080/14760584.2024.2438760

Lairun Jin, Pengfei Jin, Xuefeng Zhang, Fengcai Zhu, Jingxin Li

{"title":"Application of reverse cumulative distribution curve and scaled logit model in determining optimal immunogenic dose and prediction of protection of EV71 vaccines.","authors":"Lairun Jin, Pengfei Jin, Xuefeng Zhang, Fengcai Zhu, Jingxin Li","doi":"10.1080/14760584.2024.2438760","DOIUrl":"10.1080/14760584.2024.2438760","url":null,"abstract":"Background: This study proposes the reverse cumulative distribution curve (RCDC) for optimal dose selection and a scaled logit model for estimating protection in EV71 vaccine development.Research design and methods: Data were from a phase 2 trial involving infants and young children randomized to receive either 640 U with or without adjuvant, 320 U with adjuvant, 160 U with adjuvant EV71 vaccines, or placebo. RCDCs were constructed using neutralizing antibody titers 28 days post-vaccination. Robustness of RCDC parameters was assessed via coefficient of variation for the area under the curve (AUC), the relative optimal point, median on the curve, and antibody titer of the point of maximum curvature, with geometric mean titer (GMT) as control. The scaled logit model estimated protection against EV71-associated disease for the selected optimal dose.Results: The AUC and relative optimal point demonstrated greater robustness than GMT. The 640 U with adjuvant dose had the highest AUC (0.64, 95% CI: 0.61-0.66), sum of coordinates of the relative optimal point (1.40, 95% CI: 1.34-1.43), and the highest estimated protection (93.36%, 95% CI: 79.91-97.86).Conclusions: AUC and relative optimal point of RCDC are effective for early vaccine dose screening, with protection estimated by the scaled logit model.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"37-44"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine. 意外接触四价登革热减毒活疫苗 TAK-003 后的妊娠结局。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-03-27 DOI: 10.1080/14760584.2025.2480297

Martina Rauscher, Zeb Youard, Alice Faccin, Sanjay S Patel, Hang Pang, Olaf Zent

{"title":"Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine.","authors":"Martina Rauscher, Zeb Youard, Alice Faccin, Sanjay S Patel, Hang Pang, Olaf Zent","doi":"10.1080/14760584.2025.2480297","DOIUrl":"10.1080/14760584.2025.2480297","url":null,"abstract":"Background: The tetravalent dengue vaccine TAK-003 is contraindicated during pregnancy. Pregnant women were excluded from TAK-003 clinical studies; however, some pregnancies occurred unintentionally.Research design and methods: This post-hoc analysis of phase 2 and 3 studies, evaluated pregnancy outcomes and neonatal adverse events (AEs) following unintentional vaccination during the time period ('exposure window') when women could be pregnant (within 44 days before last menstrual period until the outcome of pregnancy).Results: Of the 557 reported pregnancies, 38 (TAK-003, n = 28/375; placebo, n = 10/182) occurred inside the exposure window. Of these, 28 (TAK-003, n = 23; placebo, n = 5) resulted in live births, four resulted in elective terminations (TAK-003, n = 2; placebo, n = 2), five in spontaneous abortions (TAK-003, n = 3; placebo, n = 2) and one unknown outcome (placebo).Of the spontaneous abortions, there was no significant difference between TAK-003 and placebo recipients, or between those occurring within or outside the exposure window. Six participants who received TAK-003 in the exposure window and two neonates experienced serious AEs; none were considered TAK-003 related.Conclusions: This post-hoc analysis found no evidence of increased adverse pregnancy outcomes following unintentional TAK-003 vaccination occurring inside the exposure window compared with placebo.Clinical trial registration: The clinical trials from which data were extracted are registered at www.clinicaltrials.gov (identifiers are NCT02193087, NCT01511250, NCT02302066, NCT02425098, NCT03746015, NCT02747927, NCT03999996, NCT03423173, NCT03342898, NCT03771963, NCT04313244, NCT02948829, NCT035252119, NCT03341637).","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"221-229"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Protection and waning of vaccine-induced, natural and hybrid immunity to SARS-CoV-2 in Hong Kong.

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-03-30 DOI: 10.1080/14760584.2025.2485252

Jialiang Jiang, Kwok Fai Lam, Eric Ho Yin Lau, Guosheng Yin, Yun Lin, Benjamin John Cowling

{"title":"Protection and waning of vaccine-induced, natural and hybrid immunity to SARS-CoV-2 in Hong Kong.","authors":"Jialiang Jiang, Kwok Fai Lam, Eric Ho Yin Lau, Guosheng Yin, Yun Lin, Benjamin John Cowling","doi":"10.1080/14760584.2025.2485252","DOIUrl":"10.1080/14760584.2025.2485252","url":null,"abstract":"Background: As the COVID-19 pandemic transitions into its fourth year, understanding the dynamics of immunity is critical for implementing effective public health measures. This study examines vaccine-induced, natural, and hybrid immunity to SARS-CoV-2 in Hong Kong, focusing on their protective effectiveness and waning characteristics against infection during the Omicron BA.1/2 dominant period.Research design and methods: We conducted a territory-wide retrospective cohort study using vaccination and infection records from the Hong Kong Department of Health. The analysis included over 6.5 million adults, applying the Andersen-Gill model to estimate protective effectiveness while addressing selection bias through inverse probability weighting.Results: Vaccine-induced immunity peaked one month after the first dose but waned rapidly, while boosters significantly prolonged protection. Infection-induced immunity showed higher initial effectiveness but declined faster than vaccine-induced immunity. Hybrid immunity provided the most durable protection. mRNA vaccines (Comirnaty) demonstrated greater effectiveness and slower waning compared to inactivated vaccines (CoronaVac).Conclusions: Hybrid immunity represents the most effective strategy for sustained protection against SARS-CoV-2. Public health policies should emphasize booster campaigns and hybrid immunity pathways to enhance population-level immunity and guide future COVID-19 management in Hong Kong.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"252-260"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Estimating the potential public health and economic impact of vaccination strategies with an adapted vaccine in Colombia using a combined Markov-decision tree model.

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-03-30 DOI: 10.1080/14760584.2025.2485251

Jair Alberto Arciniegas, Juan Manuel Reyes, Carlos Fernando Mendoza, Iustina Chirila, Moe Hein Kyaw, Omar Escobar, Jorge Enrique La Rotta, Ben Yarnoff

{"title":"Estimating the potential public health and economic impact of vaccination strategies with an adapted vaccine in Colombia using a combined Markov-decision tree model.","authors":"Jair Alberto Arciniegas, Juan Manuel Reyes, Carlos Fernando Mendoza, Iustina Chirila, Moe Hein Kyaw, Omar Escobar, Jorge Enrique La Rotta, Ben Yarnoff","doi":"10.1080/14760584.2025.2485251","DOIUrl":"10.1080/14760584.2025.2485251","url":null,"abstract":"Background: Using adapted COVID-19 vaccines targeting current variants in circulation is necessary for addressing the dynamic evolution of the SARS-CoV-2 virus and protecting against emerging variants. This study evaluated the impact of various vaccination strategies with an adapted vaccine in Colombia.Research design and methods: Using a previously published combined Markov-decision tree model adapted for the Colombia context, this study estimated the outcomes of different vaccination strategies targeting various age and risk groups. The model used age-specific epidemiology, clinical, cost, and quality of life inputs derived from the published literature and national surveillance data. Scenario and sensitivity analyses were conducted to assess uncertainty.Results: Compared to no vaccination, the vaccination strategy targeting older adults aged ≥65 years and the high-risk population was estimated to prevent 306,460 symptomatic cases, 5,200 hospitalizations, 3,381 deaths, and 39,454 lost QALYs, translating to total direct and societal cost savings of USD 70,840,305 and USD 128,918,995, respectively. These gains were further increased by expanding vaccination to additional age groups. Results were most sensitive to parameters for the attack rate and duration of protection.Conclusions: Implementing vaccination strategies targeting a broader age range with an adapted vaccine would result in considerable health and economic benefits in Colombia.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"242-251"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0